Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)-Reference-Cited by-同舟云学术

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)

Published:2016-08-04 Issue:3 Volume:19 Page:317-325
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Kentepozidis N.,Economopoulou P.,Christofyllakis Ch.,Chelis L.,Polyzos A.,Vardakis N.,Koinis F.,Vamvakas L.,Katsaounis P.,Kalbakis K.,Nikolaou Ch.,Georgoulias V.,Kotsakis A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-016-1532-y.pdf

Reference28 articles.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin. 2012;62(5):283–98 [Epub 2012/09/19].

2. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9(9):1618–26 [Epub 1991/09/01].

3. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(28):3825–31 [Epub 2011/09/09].

4. Burdett S, Stephens R, Stewart L, Tierney J, Auperin A, Le Chevalier T, et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(28):4617–25 [Epub 2008/08/06].

5. Socinski MA, Evans T, Gettinger S, Hensing TA, Sequist LV, Ireland B, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e341S–68S [Epub 2013/05/10].

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNAs as the critical regulators of autophagy-mediated cisplatin response in tumor cells;Cancer Cell International;2023-04-25

2. LINC00963: A potential cancer diagnostic and therapeutic target;Biomedicine & Pharmacotherapy;2022-06

3. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials;Translational Lung Cancer Research;2021-05

4. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route;Bioengineered;2021-01-01

5. First and Second Line Chemotherapeutic Regimens for Non-Small Cell Lung Carcinomas - The Efficacy of Platinum, Non-Platinum and Combination Therapy: A Literature Review;Cureus;2020-11-22